



JPW

PATENT  
PC25539A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 25th day of June, 2004.

By

*Sarah J. Delaney*

(Signature of person mailing)

*Sarah J. Delaney*

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

-----  
IN RE APPLICATION OF:

Justin S. Bryans, et al.

Examiner: To Be Assigned

SERIAL NO.: 10/782,285

Art Unit: To Be Assigned

FILED: February 18, 2004

FOR: TRIAZOLE COMPOUNDS USEFUL IN  
THERAPY  
-----

Mail Stop Amendment  
Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §1.97(b)(3)

Sir:

Pursuant to the provisions of 37 C.F.R. §1.97(b)(3), Applicant petitions for the entry and consideration of the supplemental Information Disclosure Statement transmitted herewith in the above-identified case.


Pursuant to the provisions of M.P.E.P. 1302.12, it is requested that the references listed on the attached form, which complies with PTO-FB-A820, be included in the "References Cited" portion of any patent issuing from this application.

Pursuant to the provisions of 37 C.F.R. §1.97(e)(1), Applicant's undersigned representative certifies that each item of information contained in the supplemental Information Disclosure Statement was first cited in a counterpart foreign application not more than three (3) months prior to the date of the filing of this supplemental Information Disclosure Statement.


Pursuant to the provisions of 37 C.F.R. §1.97(c), no fee for the filing of this supplemental Information Disclosure Statement is due.

Respectfully submitted,

Date: June 25, 2004

  
Carl J. Goddard  
Attorney for Applicant  
Reg. No. 39,203  
Tel.: (860) 441-4902

PFIZER INC  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, CT 06340  
(860) 441-4902



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)									ATTY. DOCKET NO. PC25539A			SERIAL NO. 10/782,285		
									APPLICANT Justin Stephen Bryans et al.					
									FILING DATE February 18, 2004			GROUP To be assigned		
U.S. PATENT DOCUMENTS														
EXAMINER INITIAL	DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
		5	4	3	8	0	3	5	01.08.95	Guaciaro et. al	504/191		24.06.94	
FOREIGN PATENT DOCUMENTS														
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	WO	02	0	8	3	6	7	8	24.10.02	International	C07D	487/04		
	WO	0	0	4	3	3	9	8	27.07.00	International	C07D	498/04		
	WO	9	8	2	0	0	1	1	14.05.98	International	C07D	487/04		
	EP	0	3	6	2	9	4	2	29.09.89	EP	C07D	498/04		
	WO	9	7	4	9	7	0	7	31.12.97	International	C07D	487/04		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)														
			Breslin, H., et al., Synthesis and Anti-HIV Activity of 1,3,4,5-Tetrahydro-2H-1,4-benzodiazepin-2-one (TBO) Derivatives. Truncated 4,5,6,7-Tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-ones (TIBO) Analogues, Pergamon Bioorganic & Medicinal Chemistry, 7 (1999) pp. 2427 -2436, May 20, 1999.											
			Ashwood, Michael, S. et al., Synthesis of 5,6-Dihydro-4H-imidazo[1,5-a][4,1]benzoxazepin-6-ones and their Transformation into 5,6-Dihydro-4H-imidazo[1,5-a][1,4]benzodiazepin-6-ones, J. Chem. Soc. Perkin Trans. I, 1989, pp.1889-1893.											
			Goel, O.P., Reaction of Phosphorus Pentasulfide with Organolithiums. An <i>In Situ</i> Reagent for the Preparation of Thiolactams, Dept. of Chemistry, Warner-Lambert/Parke-Davis Pharmaceuticals Research, Communications, February 1987, pp.162-164.											
EXAMINER														
DATE CONSIDERED														
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														